Robin Davison


Robin is an independent biotech/pharma industry analyst and commentator and has been a regular contributor to Vantage since 2015.

Among other projects, he is currently involved in setting up a new healthcare investment vehicle.

He was previously an equity research analyst Edison Investment Research, where he established and headed the healthcare research team alongside Jacob Plieth. Earlier in his career he was a journalist and editor at Scrip.